314 related articles for article (PubMed ID: 17290398)
1. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB.
Oka D; Nishimura K; Shiba M; Nakai Y; Arai Y; Nakayama M; Takayama H; Inoue H; Okuyama A; Nonomura N
Int J Cancer; 2007 Jun; 120(12):2576-81. PubMed ID: 17290398
[TBL] [Abstract][Full Text] [Related]
2. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis.
Fang LJ; Shao XT; Wang S; Lu GH; Xu T; Zhou JY
Planta Med; 2010 Feb; 76(3):258-64. PubMed ID: 19774508
[TBL] [Abstract][Full Text] [Related]
3. Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells.
Kishida Y; Yoshikawa H; Myoui A
Clin Cancer Res; 2007 Jan; 13(1):59-67. PubMed ID: 17200339
[TBL] [Abstract][Full Text] [Related]
4. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
[TBL] [Abstract][Full Text] [Related]
5. Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer.
Sohma I; Fujiwara Y; Sugita Y; Yoshioka A; Shirakawa M; Moon JH; Takiguchi S; Miyata H; Yamasaki M; Mori M; Doki Y
Cancer Genomics Proteomics; 2011; 8(1):39-47. PubMed ID: 21289336
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo.
Nakabayashi H; Shimizu K
BMC Cancer; 2012 Oct; 12():453. PubMed ID: 23039130
[TBL] [Abstract][Full Text] [Related]
7. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Ralstin MC; Gage EA; Yip-Schneider MT; Klein PJ; Wiebke EA; Schmidt CM
Mol Cancer Res; 2006 Jun; 4(6):387-99. PubMed ID: 16778086
[TBL] [Abstract][Full Text] [Related]
8. Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo.
Zhang D; Qiu L; Jin X; Guo Z; Guo C
Mol Cancer Res; 2009 Jul; 7(7):1139-49. PubMed ID: 19584264
[TBL] [Abstract][Full Text] [Related]
10. Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation.
Kiuchi H; Takao T; Yamamoto K; Nakayama J; Miyagawa Y; Tsujimura A; Nonomura N; Okuyama A
J Urol; 2009 May; 181(5):2339-48. PubMed ID: 19303104
[TBL] [Abstract][Full Text] [Related]
11. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway.
Manu KA; Shanmugam MK; Ramachandran L; Li F; Fong CW; Kumar AP; Tan P; Sethi G
Clin Cancer Res; 2012 Apr; 18(8):2220-9. PubMed ID: 22351692
[TBL] [Abstract][Full Text] [Related]
12. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells.
Watson C; Miller DA; Chin-Sinex H; Losch A; Hughes W; Sweeney C; Mendonca MS
Radiat Res; 2009 Apr; 171(4):389-96. PubMed ID: 19397439
[TBL] [Abstract][Full Text] [Related]
13. Role of NF-κB activation in matrix metalloproteinase 9, vascular endothelial growth factor and interleukin 8 expression and secretion in human breast cancer cells.
Li C; Guo S; Shi T
Cell Biochem Funct; 2013 Apr; 31(3):263-8. PubMed ID: 23086737
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models.
Gao ZW; Zhang DL; Guo CB
Curr Cancer Drug Targets; 2010 Nov; 10(7):705-15. PubMed ID: 20578985
[TBL] [Abstract][Full Text] [Related]
16. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Harada K; Supriatno ; Yoshida H; Sato M
Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
[TBL] [Abstract][Full Text] [Related]
17. The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro.
Arai Y; Nonomura N; Nakai Y; Nishimura K; Oka D; Shiba M; Nakayama M; Takayama H; Mizutani Y; Miki T; Okuyama A
Cancer Invest; 2008 Feb; 26(1):35-40. PubMed ID: 18181043
[TBL] [Abstract][Full Text] [Related]
18. Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo.
Tian F; Fan T; Zhang Y; Jiang Y; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):847-55. PubMed ID: 23017833
[TBL] [Abstract][Full Text] [Related]
19. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE
Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823
[TBL] [Abstract][Full Text] [Related]
20. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
Yip-Schneider MT; Nakshatri H; Sweeney CJ; Marshall MS; Wiebke EA; Schmidt CM
Mol Cancer Ther; 2005 Apr; 4(4):587-94. PubMed ID: 15827332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
